Gilead Sciences (GILD) investor relations material

Company overview and strategy

• Focuses on HIV, oncology, and inflammation, with HIV as the foundational business and ongoing diversification efforts over the past six years.

• Recent earnings showed a strong start to 2026, with updated guidance up $400 million, mainly driven by HIV products and strong performance from Trodelvy.

• Completed three acquisitions: Arcellx (cell therapy), Tubulis (oncology), and Ouro (inflammation), with Arcellx closed and the others expected to close this quarter.

• No major loss of exclusivity expected until 2036, providing a stable platform for growth and strategic investments.

Recent acquisitions and pipeline development

• Acquisitions were not strictly planned to coincide but resulted from a high bar for science and existing collaborations, especially with Arcellx and Tubulis.

• Arcellx acquisition leverages an existing partnership, with anito-cel expected to launch for fourth-line multiple myeloma (PDUFA date late December), targeting a $3.5 billion market initially and potentially expanding to a $20 billion market.

• Tubulis brings a promising ADC platform, with potential for higher efficacy and safety in oncology, building on experience with Trodelvy.

• Ouro acquisition targets orphan diseases in inflammation, with subcutaneous BCMA CD3 T-cell engager offering potential for sustained response and future pipeline expansion.

Oncology franchise and product launches

• Trodelvy showed 37% Q1 growth, driven by practice-changing data in triple-negative breast cancer and new NCCN guidelines, with anticipated first-line approval in the second half of the year.

• Expansion into earlier lines of therapy for anito-cel in multiple myeloma is planned, supported by a large network of Authorized Treatment Centers and operational readiness.

• Oncology franchise now exceeds $3 billion, with further growth expected from new launches and pipeline assets.